Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796182 | 1.00 | CA2 (0.42) | CA2LPLLIPGACHENFE2L2 | |
| Methylene Chloride SCHEMBL28972114 | 0.92 | CA2 (0.37) | CA2LPLLIPGACHENFE2L2 | |
| SCHEMBL17083197 | 0.83 | CA2 (0.41) | CA2LPLLIPGACHEORAI1 | |
| SCHEMBL29426987 | 0.81 | CA2 (0.42) | CA2LPLLIPGACHENFE2L2 | |
| SCHEMBL1372258 | 0.81 | CA2 (0.42) | CA2LPLLIPGACHENFE2L2 | |
| SCHEMBL14753490 | 0.78 | ACHE (0.45) | ACHETP53 | |
| SCHEMBL12384874 | 0.78 | ESR2 (0.36) | HSD17B10 | |
| SCHEMBL39406 | 0.78 | CES2 (0.43) | ACHENFE2L2ORAI1ORAI2ORAI3 | |
| SCHEMBL29395656 | 0.78 | CES2 (0.43) | ACHENFE2L2ORAI1ORAI2ORAI3 | |
| SCHEMBL15646351 | 0.76 | CA2 (0.42) | CA2LPLLIPGCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 590 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | claimed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | claimed |
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | claimed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | claimed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | claimed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | claimed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | claimed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115487361-A | Hydrophilic antibacterial anti-inflammatory hydrogel film and preparation method and application thereof | 四川大学 | 2022-12-20 | — | — | CN | claimed |
| CN-115232090-A | 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2022-10-25 | — | — | CN | claimed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | claimed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | claimed |
| CN-106636043-B | Method for producing protease | 广州立白企业集团有限公司 | 2020-04-07 | — | — | CN | claimed |
| CN-103289033-A | Aryl boron-containing phenolic resin and preparation method thereof | UNIV XI AN JIAOTONG | 2013-09-11 | — | — | CN | claimed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | GIVAUDAN SA (CH) | 2026-04-16 | — | — | US | disclosed |
| EP-4146220-B1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12528801-B2 | Substituted azacyles as TRPM8 modulators | GIVAUDAN SA (CH) | 2026-01-20 | — | — | US | disclosed |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2025-12-04 | — | — | US | disclosed |
| EP-3909964-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2025-10-08 | — | — | EP | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-12402638-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| US-20250194617-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-06-19 | — | — | US | disclosed |
| WO-2025111513-A1 | COMPOUNDS USEFUL IN THE MODULATION OF KLHDC1 AND KLHDC2 ACTIVITY | NURIX THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-20250169514-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-20250066401-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-02-27 | — | — | US | disclosed |
| US-12232516-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| CN-119431358-A | Pyrrolopyridines, compositions thereof and their use in medicine | 中国科学院上海药物研究所 | 2025-02-14 | — | — | CN | disclosed |
| US-20250042897-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-12193465-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2025-01-14 | — | — | US | disclosed |
| CN-118164880-B | Biphenyl trifluoro ethylsulfide compound and application thereof | 沈阳中化农药化工研发有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-12152042-B2 | Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-11-26 | — | — | US | disclosed |
| CN-115232090-B | 6-Substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2, 2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2024-11-19 | — | — | CN | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024233848-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240352023-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-10-24 | — | — | US | disclosed |
| EP-4430029-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Vigil Neuroscience, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| CN-112979524-B | 6, 7-Dihydro-5H-benzo [7] rotaene derivatives as estrogen receptor modulators | 赛诺菲 | 2024-09-10 | — | — | CN | disclosed |
| US-12037338-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240216357-A1 | POLYCYCLIC COMPOUND AND APPLICATION THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-118239818-A | Preparation method of fluorobiphenyl compound | 沈阳中化农药化工研发有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20240190863-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-118164880-A | Biphenyl trifluoro ethylsulfide compound and application thereof | 沈阳中化农药化工研发有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240150284-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2024-05-09 | — | — | US | disclosed |
| US-20240132487-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | GIVAUDAN SA (CH) | 2024-04-25 | — | — | US | disclosed |
| US-20240124446-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4328222-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | Voronoi Inc. (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024016826-A1 | 6-POSITION SUBSTITUTED DIHYDROBENZO[E][1,2,3]OXATHIAZINE 2,2-DIOXIDE COMPOUND, PREPARATION THEREFOR, AND USE THEREOF | 杭州市第七人民医院 | 2024-01-25 | — | — | WO | disclosed |
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230380457-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-30 | — | — | US | disclosed |
| EP-4280882-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-114989085-B | Aryl lactam ring compound, pharmaceutical composition and application thereof | 安徽医科大学 | 2023-11-24 | — | — | CN | disclosed |
| US-20230363426-A1 | Materials and Methods for Extending Shelf-Life of Foods | JP LABORATORIES, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-117062813-A | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |
| EP-3842436-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | SK BIOPHARMACEUTICALS CO LTD (KR) | 2023-11-08 | — | — | EP | disclosed |
| US-11793220-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116916755-A | Materials and methods for extending the shelf life of food products | JP实验室公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| US-11767320-B2 | Bicyclic dione compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-11737481-B2 | Materials and methods for extending shelf-life of foods | JP LABORATORIES, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-113929635-B | 1, 6-diphenyl-1H-benzo [ d ] [1,2,3] triazole compound and preparation method and application thereof | 沈阳药科大学 | 2023-08-22 | — | — | CN | disclosed |
| US-11718617-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells2 agonists and methods of use | AMGEN INC. (US) | 2023-08-08 | — | — | US | disclosed |
| CN-110740991-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2023-07-04 | — | — | CN | disclosed |
| US-20230192739-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-06-22 | — | — | US | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086800-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115724842-A | Pyrimidone derivatives and their use in medicine | 广东东阳光药业有限公司 | 2023-03-03 | — | — | CN | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-01-05 | — | — | US | disclosed |
| EP-4104861-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2022-12-21 | — | — | EP | disclosed |
| CN-115487361-A | Hydrophilic antibacterial anti-inflammatory hydrogel film and preparation method and application thereof | 四川大学 | 2022-12-20 | — | — | CN | disclosed |
| US-11510915-B2 | Anti-tumor effect potentiator using novel biphenyl compound | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-11-29 | — | — | US | disclosed |
| CN-115397467-A | Therapeutic agent for tauopathy | 住友制药株式会社 | 2022-11-25 | — | — | CN | disclosed |
| CN-115232090-A | 6-substituted dihydrobenzo [ e ] [1,2,3] oxathiazine 2,2-dioxide compound and preparation and application thereof | 杭州市第七人民医院 | 2022-10-25 | — | — | CN | disclosed |
| US-11479563-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-10-25 | — | — | US | disclosed |
| CN-113444038-B | 2-aryl isonicotinic acid amide LSD1/HDAC double-target inhibitor, and preparation method and application thereof | 新乡医学院 | 2022-09-27 | — | — | CN | disclosed |
| EP-4059934-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | Novartis AG (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-113527195-B | 5-aryl nicotinamide LSD1/HDAC double-target inhibitor, preparation method and application thereof | 新乡医学院 | 2022-09-20 | — | — | CN | disclosed |
| CN-114989085-A | Aryl lactam ring compound, pharmaceutical composition and application thereof | 安徽医科大学 | 2022-09-02 | — | — | CN | disclosed |
| US-20220264914-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-08-25 | — | — | US | disclosed |
| EP-4045491-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | Givaudan SA (CH) | 2022-08-24 | — | — | EP | disclosed |
| CN-111440137-B | 3, 4-benzocoumarin derivative and preparation method and application thereof | 华东理工大学 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022159439-A2 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220225646-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| US-20220225647-A1 | MATERIALS AND METHODS FOR EXTENDING SHELF-LIFE OF FOODS | JP LABORATORIES, INC. | 2022-07-21 | — | — | US | disclosed |
| CN-111592487-B | Hydroximic acid group-containing diarylethene LSD1/HDACs double-target inhibitor, and preparation method and application thereof | 新乡医学院 | 2022-07-19 | — | — | CN | disclosed |
| CN-109963848-B | Substituted N- (3-fluoropropyl) -pyrrolidine compounds, preparation thereof and therapeutic use thereof | 赛诺菲 | 2022-07-05 | — | — | CN | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| CN-114555594-A | Substituted azaheterocycles as TRMP8 modulators | 奇华顿股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113444069-B | 2-aryl-4- (1H-pyrazol-3-yl) pyridine LSD1/HDAC double-target inhibitor | 新乡医学院 | 2022-05-03 | — | — | CN | disclosed |
| WO-2022072783-A1 | BICYCLIC DIONE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20220106309-A1 | BICYCLIC DIONE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2022-04-07 | — | — | US | disclosed |
| US-20220073460-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-03-10 | — | — | US | disclosed |
| CN-114106056-A | Metal organic light-emitting material and application thereof in OLED device | 北京燕化集联光电技术有限公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-108602770-B | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2022-02-08 | — | — | CN | disclosed |
| CN-113929635-A | 1, 6-diphenyl-1H-benzo [ d ] [1,2,3] triazole compound and preparation method and application thereof | 沈阳药科大学 | 2022-01-14 | — | — | CN | disclosed |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2022-01-04 | — | — | US | disclosed |
| EP-3510033-B1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-11-24 | — | — | EP | disclosed |
| CN-113666967-A | Organometallic compound, organic light emitting device including the same, and electronic apparatus including the organic light emitting device | 三星电子株式会社 | 2021-11-19 | — | — | CN | disclosed |
| US-20210355148-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-11-18 | — | — | US | disclosed |
| EP-3524600-B1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS | SANOFI SA (FR) | 2021-11-17 | — | — | EP | disclosed |
| EP-3909964-A2 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2021-11-17 | — | — | EP | disclosed |
| CN-113527195-A | 5-aryl nicotinamide LSD1/HDAC double-target inhibitor, preparation method and application thereof | 新乡医学院 | 2021-10-22 | — | — | CN | disclosed |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2021-10-21 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20210300933-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-09-30 | — | — | US | disclosed |
| CN-113444038-A | 2-aryl isonicotinic acid amide LSD1/HDAC double-target inhibitor, and preparation method and application thereof | 新乡医学院 | 2021-09-28 | — | — | CN | disclosed |
| CN-113444069-A | 2-aryl-4- (1H-pyrazol-3-yl) pyridine LSD1/HDAC double-target inhibitor | 新乡医学院 | 2021-09-28 | — | — | CN | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021141041-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | 大日本住友製薬株式会社 | 2021-07-15 | — | — | WO | disclosed |
| EP-3523277-B1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE OVERSEAS SARL (LU) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842436-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZOPYRIMIDINE OR IMIDAZOTRIAZINE DERIVATIVES FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | SK Biopharmaceuticals Co., Ltd. (KR) | 2021-06-30 | — | — | EP | disclosed |
| US-11046702-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2021-06-29 | — | — | US | disclosed |
| CN-112979524-A | 6, 7-dihydro-5H-benzo [7] annulene derivatives as estrogen receptor modulators | 赛诺菲 | 2021-06-18 | — | — | CN | disclosed |
| US-20210179634-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| EP-3416962-B1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI SA (FR) | 2021-05-05 | — | — | EP | disclosed |
| EP-3814347-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | Bristol-Myers Squibb Company (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-108026050-B | Novel compounds as ROR gamma modulators | 格兰马克药品股份有限公司 | 2021-04-30 | — | — | CN | disclosed |
| US-10988467-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2021-04-27 | — | — | US | disclosed |
| WO-2021074281-A1 | SUBSTITUTED AZACYLES AS TRMP8 MODULATORS | GIVAUDAN SA (CH) | 2021-04-22 | — | — | WO | disclosed |
| EP-3342767-B1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-20210101902-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS AG (CH) | 2021-04-08 | — | — | US | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10954233-B2 | Compounds and compositions as inhibitors of endosomal toll-like receptors | NOVARTIS AG (CH) | 2021-03-23 | — | — | US | disclosed |
| CN-108884079-B | 6, 7-dihydro-5H-benzo [7] annulene derivatives as estrogen receptor modulators | 赛诺菲 | 2021-03-05 | — | — | CN | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
| US-20210053926-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| EP-2860178-B1 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3262047-B1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO LTD (KR) | 2021-01-06 | — | — | EP | disclosed |
| US-20200392123-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200392081-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-12-17 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-10781184-B2 | Substituted benzazinones as antibacterial compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20200277298-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2020-09-03 | — | — | US | disclosed |
| CN-111592487-A | Hydroximic acid group-containing diarylethene LSD1/HDACs double-target inhibitor, and preparation method and application thereof | 新乡医学院 | 2020-08-28 | — | — | CN | disclosed |
| EP-3686187-A1 | PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2020-07-29 | — | — | EP | disclosed |
| US-10723742-B2 | Biphenyl compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| CN-111440137-A | 3, 4-benzocoumarin derivative and preparation method and application thereof | 华东理工大学 | 2020-07-24 | — | — | CN | disclosed |
| US-10689372-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| EP-3632443-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632897-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| CN-106279101-B | Benzopyrazolopyridines, pharmaceutical compositions comprising same and use thereof | 中国科学院上海药物研究所 | 2020-03-17 | — | — | CN | disclosed |
| EP-3331863-B1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2020-03-11 | — | — | EP | disclosed |
| US-10570090-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2020-02-25 | — | — | US | disclosed |
| CN-110740991-A | Novel biphenyl compound or salt thereof | 大鹏药品工业株式会社 | 2020-01-31 | — | — | CN | disclosed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-107635994-B | Imidazopyrimidine and imidazo-triazine derivative and the pharmaceutical composition comprising it | 爱思开生物制药株式会社 | 2019-11-05 | — | — | CN | disclosed |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2019-10-17 | — | — | US | disclosed |
| EP-3541809-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2019-09-25 | — | — | EP | disclosed |
| US-20190270731-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-10399940-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-09-03 | — | — | US | disclosed |
| US-20190256508-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2019-08-22 | — | — | US | disclosed |
| EP-3524600-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS | Sanofi (FR) | 2019-08-14 | — | — | EP | disclosed |
| EP-3523277-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190211009-A1 | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-07-11 | — | — | US | disclosed |
| US-10344024-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2019-07-09 | — | — | US | disclosed |
| EP-3495348-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2019-06-12 | — | — | EP | disclosed |
| EP-2215049-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190083474-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2019-03-21 | — | — | US | disclosed |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-07 | — | — | US | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-02-07 | — | — | US | disclosed |
| US-20190031669-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. | 2019-01-31 | — | — | US | disclosed |
| EP-3416962-A1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-20180362474-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| US-20180354960-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-3409671-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2018-12-05 | — | — | EP | disclosed |
| US-10118922-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3114126-B1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-10106544-B2 | 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-10-23 | — | — | US | disclosed |
| EP-3386950-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-10100057-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2018-10-16 | — | — | US | disclosed |
| EP-3381896-A1 | NOVEL BIPHENYL COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-10-03 | — | — | EP | disclosed |
| US-10065953-B2 | Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180237428-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2018-08-23 | — | — | US | disclosed |
| US-20180222901-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
| EP-3342767-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3331863-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2018-06-13 | — | — | EP | disclosed |
| US-9980948-B2 | Azaindole derivative having AMPK-activating activity | SHIONOGI & CO., LTD. (JP) | 2018-05-29 | — | — | US | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
| US-9975887-B2 | Compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2018-05-22 | — | — | US | disclosed |
| EP-3114123-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-25 | — | — | EP | disclosed |
| US-20180099932-A1 | Substituted Pyrrolidines and Methods of Use | GALAPAGOS NV (BE) | 2018-04-12 | — | — | US | disclosed |
| WO-2018065921-A1 | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018063955-A1 | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2018-04-05 | — | — | WO | disclosed |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2018-03-22 | — | — | US | disclosed |
| US-20180079720-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-03-22 | — | — | US | disclosed |
| US-20180030039-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2018-02-01 | — | — | US | disclosed |
| EP-3262047-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK Biopharmaceuticals Co., Ltd. (KR) | 2018-01-03 | — | — | EP | disclosed |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | disclosed |
| US-9849117-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-12-26 | — | — | US | disclosed |
| US-20170349597-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| US-20170273955-A1 | AZAINDOLE DERIVATIVE HAVING AMPK-ACTIVATING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-28 | — | — | US | disclosed |
| US-9745310-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2017-08-29 | — | — | US | disclosed |
| WO-2017140669-A1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS | SANOFI (FR) | 2017-08-24 | — | — | WO | disclosed |
| US-20170233340-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20170233380-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9714221-B1 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2017-07-25 | — | — | US | disclosed |
| EP-3186254-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-07-05 | — | — | EP | disclosed |
| US-9695168-B2 | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2841433-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL CO (JP) | 2017-06-21 | — | — | EP | disclosed |
| WO-2017098440-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| CN-104245689-B | Terazololine-one compound and its purposes as insecticide | 住友化学株式会社 | 2017-06-06 | — | — | CN | disclosed |
| US-9663500-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2017-04-27 | — | — | US | disclosed |
| US-20170107223-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-20 | — | — | US | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-9598450-B2 | Emissive compounds for organic light-emitting diodes | NITTO DENKO CORPORATION (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9598450-B2 | Emissive compounds for organic light-emitting diodes | NITTO DENKO CORPORATION (JP) | 2017-03-21 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| EP-2731436-B1 | 2-(PYRROLO[2,3-B]PYRIDINE-5-YL)-2-(T-BUTOXY)-ACETIC ACID DERIVATIVES AS HIV REPLICATION INHIBITORS FOR THE TREATMENT OF AIDS | VIIV HEALTHCARE UK LTD (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-9573943-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | GENENTECH, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9565856-B2 | Tetrazolinone compounds and its use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9567343-B2 | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2017-02-14 | — | — | US | disclosed |
| WO-2017021879-A1 | NOVEL COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-02-09 | — | — | WO | disclosed |
| EP-2794593-B1 | SPIRO AMINIC COMPOUNDS AS OREXIN ANTAGONISTS | Rottapharm Biotech Srl (IT) | 2017-02-01 | — | — | EP | disclosed |
| EP-3121167-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | Hyundai Pharm Co., Ltd. (KR) | 2017-01-25 | — | — | EP | disclosed |
| EP-3114123-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica NV (BE) | 2017-01-11 | — | — | EP | disclosed |
| EP-3114126-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Actelion Pharmaceuticals Ltd (CH) | 2017-01-11 | — | — | EP | disclosed |
| CN-106279101-A | Benzopyrazoles bipyridyliums compound, comprise the medical composition and its use of this compounds | 中国科学院上海药物研究所 | 2017-01-04 | — | — | CN | disclosed |
| EP-2640729-B1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355483-A1 | COMPOUND BINDING TO PPARG BUT NOT ACTING AS PROMOTER AND PHARMACEUTICAL COMPOSITION FOR TREATING PPARG-RELATED DISEASES CONTAINING SAME AS ACTIVE INGREDIENT | HYUNDAI PHARM CO., LTD. (KR) | 2016-12-08 | — | — | US | disclosed |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| US-9512089-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512089-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512089-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | disclosed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | disclosed |
| EP-2556066-B1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2016-10-19 | — | — | EP | disclosed |
| CN-101686989-B | Substituted imidazoheterocycles | 卡拉治疗学股份有限公司 | 2016-10-19 | — | — | CN | disclosed |
| US-9447116-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2016-09-20 | — | — | US | disclosed |
| WO-2016137260-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-01 | — | — | WO | disclosed |
| US-20160251361-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2016-09-01 | — | — | US | disclosed |
| EP-2592070-B1 | Tetrazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| EP-2592070-B1 | Tetrazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-9409918-B2 | Bridged bicyclic piperidine derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9380782-B2 | Tetrazolinone compounds and its use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-07-05 | — | — | US | disclosed |
| US-9315727-B2 | Compound having fluorinated naphthalene structure and liquid crystal composition of the same | DIC Corporation (Tokyo) (JP) | 2016-04-19 | — | — | US | disclosed |
| EP-2673281-B1 | BORON CONTAINING POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTICS USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3002279-A1 | Method for the preparation of 3- (5-aminotriazolyl) sulfide derivatives | Bayer CropScience AG (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2605658-B1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| WO-2016033009-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES FOR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
| EP-2970161-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2016007731-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | disclosed |
| US-20160009712-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | disclosed |
| EP-2588451-B1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-12-30 | — | — | EP | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344503-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME | INFINITY PHARMACEUTICALS INC (US) | 2015-12-03 | — | — | US | disclosed |
| US-9180123-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-20150259599-A1 | COMPOUND HAVING FLUORINATED NAPHTHALENE STRUCTURE AND LIQUID CRYSTAL COMPOSITION OF THE SAME | DIC CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| WO-2015134039-A1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015132228-A1 | 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-11 | — | — | WO | disclosed |
| US-9115151-B2 | Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof | ABBVIE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115151-B2 | Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof | ABBVIE INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9108989-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2226317-B1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL IND CO (JP) | 2015-08-12 | — | — | EP | disclosed |
| EP-2718264-B1 | BENZOCYCLOHEPTENE ACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-20150191455-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2015-07-02 | — | — | US | disclosed |
| US-9067898-B1 | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9062033-B2 | Chemical compounds | ROTTAPHARM BIOTECH S.R.L. (IT) | 2015-06-23 | — | — | US | disclosed |
| US-9040704-B2 | Fluorescent dyes with large stokes shifts | UTI LIMITED PARTNERSHIP (CA) | 2015-05-26 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9018384-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-9012478-B2 | Pyrazolyl substituted carbonic acid derivatives as modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012651-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012451-B2 | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists | NOVARTIS AG (CH) | 2015-04-21 | — | — | US | disclosed |
| EP-2860178-A2 | P2X3 receptor antagonists for treatment of pain | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-9006450-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20150080340-A1 | BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2015-03-19 | — | — | US | disclosed |
| US-20150065506-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065506-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065506-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2015-03-05 | — | — | US | disclosed |
| EP-2841429-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| EP-2841433-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | Sumitomo Chemical Company Limited (JP) | 2015-03-04 | — | — | EP | disclosed |
| US-20150051195-A1 | NOVEL VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051171-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| EP-2358371-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2015-02-11 | — | — | EP | disclosed |
| US-20150031733-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8933018-B2 | Boron containing polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8906906-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-12-09 | — | — | US | disclosed |
| US-20140357653-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2014-12-04 | — | — | US | disclosed |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2512474-B1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2794593-A1 | CHEMICAL COMPOUNDS | Rottapharm Biotech S.r.l. (IT) | 2014-10-29 | — | — | EP | disclosed |
| US-20140315927-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-8859538-B2 | Uses of substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014159054-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-02 | — | — | WO | disclosed |
| US-8846933-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846945-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | DILLON MICHAEL PATRICK (US) | 2014-09-30 | — | — | US | disclosed |
| US-8841336-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841336-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841336-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140275179-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822503-B2 | 2-pyridone compounds | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-09-02 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8815840-B2 | Carbazole and carboline kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-26 | — | — | US | disclosed |
| US-8809363-B2 | Inhibitors of HIV replication | VIIV HEALTHCARE UK LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| EP-2570407-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2570407-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2234989-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2234989-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | WUXI APPTECH (SHANGHAI) CO., LTD. (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | WUXI APPTECH (SHANGHAI) CO., LTD. (CN) | 2014-07-24 | — | — | US | disclosed |
| US-20140206870-A1 | FLUORSCENT DYES WITH LARGE STOKES SHIFTS | UTI LIMITED PARTNERSHIP (CA) | 2014-07-24 | — | — | US | disclosed |
| US-20140171469-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014089904-A1 | TRIAZINONE COMPOUNDS | ABBVIE INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2370407-B1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8748624-B2 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| US-8742110-B2 | Spiroxazolidinone compounds | MERCK SHARP & DOHME CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-2731436-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-05-21 | — | — | EP | disclosed |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121183-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| EP-2516008-B1 | NOVEL ANTIVIRAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-04-16 | — | — | EP | disclosed |
| EP-2718264-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| US-8669361-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-03-11 | — | — | US | disclosed |
| US-8664401-B2 | N-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-03-04 | — | — | US | disclosed |
| US-8648207-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound, and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8637562-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629125-B2 | Inhibitors of fatty acid amide hydrolase | Infinty Pharmaceuticals, Inc. (US) | 2014-01-14 | — | — | US | disclosed |
| US-8609653-B2 | Azaindole compounds and methods for treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-12-17 | — | — | US | disclosed |
| US-8598209-B2 | P2X3, receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2013162077-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013162072-A1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-10-31 | — | — | WO | disclosed |
| WO-2013142087-A1 | BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES | SAREPTA THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| EP-2640729-A1 | INHIBITORS OF HIV REPLICATION | VIIV Healthcare UK Limited (GB) | 2013-09-25 | — | — | EP | disclosed |
| CN-103289033-A | Aryl boron-containing phenolic resin and preparation method thereof | UNIV XI AN JIAOTONG | 2013-09-11 | — | — | CN | disclosed |
| EP-2170350-B1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-2170350-B1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130203732-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130196971-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2615918-A1 | FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| WO-2013092893-A1 | CHEMICAL COMPOUNDS | ROTTAPHARM SPA (IT) | 2013-06-27 | — | — | WO | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130131042-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2592070-A2 | Tetrazole-substituted arylamides | F. Hoffmann-La Roche AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592070-A2 | Tetrazole-substituted arylamides | F. Hoffmann-La Roche AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-8440838-B2 | Aryl (1H-1,2,4-triazol-1-yl) compound and process for production thereof | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-8436001-B2 | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-20130109046-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20130096141-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2013-04-18 | — | — | US | disclosed |
| US-20130096141-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2013-04-18 | — | — | US | disclosed |
| US-20130087772-A1 | EMISSIVE COMPOUNDS FOR ORGANIC LIGHT-EMITTING DIODES | NITTO DENKO CORPORATION (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20130087772-A1 | EMISSIVE COMPOUNDS FOR ORGANIC LIGHT-EMITTING DIODES | NITTO DENKO CORPORATION (JP) | 2013-04-11 | — | — | US | disclosed |
| EP-2570407-A1 | Tetrazole-substituted arylamide derivatives and their use as P2x3 and/or P2x2/3 purinergic receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2013-03-20 | — | — | EP | disclosed |
| EP-2570407-A1 | Tetrazole-substituted arylamide derivatives and their use as P2x3 and/or P2x2/3 purinergic receptor antagonists | F. Hoffmann-La Roche AG (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059819-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2013023292-A1 | FLUORESCENT DYES WITH LARGE STOKES SHIFTS | UTI LIMITED PARTNERSHIP (CA) | 2013-02-21 | — | — | WO | disclosed |
| EP-2556066-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. Hoffmann-La Roche AG (CH) | 2013-02-13 | — | — | EP | disclosed |
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362061-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20130023666-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2013-01-24 | — | — | US | disclosed |
| WO-2013012649-A1 | AZAINDOLE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20130018049-A1 | Azaindole Compounds and Methods for Treating HIV | GLAXOSMITHKLINE LLC (US) | 2013-01-17 | — | — | US | disclosed |
| US-8349814-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349814-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-12-13 | — | — | US | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-8329675-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329675-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2012162407-A1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| EP-2516008-A1 | NOVEL ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-31 | — | — | EP | disclosed |
| EP-2512474-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120264223-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. | 2012-10-11 | — | — | US | disclosed |
| EP-2508513-A1 | 2-PYRIDONE COMPOUNDS | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245124-A1 | TRPV3 Modulators | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| WO-2012129491-A1 | TRPV3 MODULATORS | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20120220599-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | DILLON MICHAEL PATRICK (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214805-A1 | BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| US-8247401-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8236803-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2012-08-07 | — | — | US | disclosed |
| US-8232306-B2 | Methods for detecting sulfhydryl-containing compounds in a biological test sample | THERAVANCE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157425-A1 | NEW COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
| EP-2462122-A1 | NOVEL VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-06-13 | — | — | EP | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-20120136023-A1 | Inhibitors of HIV Replication | VIIV HEALTHCARE UK LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-05-24 | — | — | US | disclosed |
| WO-2012066442-A1 | INHIBITORS OF HIV REPLICATION | PFIZER LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012037298-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| WO-2012024183-A1 | SPIROXAZOLIDINONE COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-8101632-B2 | 5-furopyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120015944-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2012-01-19 | — | — | US | disclosed |
| US-20120015944-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2012-01-19 | — | — | US | disclosed |
| US-20120015944-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC. | 2012-01-19 | — | — | US | disclosed |
| EP-2404607-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
| EP-2399585-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2399584-A1 | Boronic acids and esters as inhibitors of fatty acid amide hydrolase | Infinity Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2011149500-A1 | EMISSIVE COMPOUNDS FOR ORGANIC LIGHT-EMITTING DIODES | NITTO DENKO CORPORATION (JP) | 2011-12-01 | — | — | WO | disclosed |
| US-8048905-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048905-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-11-01 | — | — | US | disclosed |
| US-8048905-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2011-11-01 | — | — | US | disclosed |
| WO-2011124580-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-13 | — | — | WO | disclosed |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-10-13 | — | — | US | disclosed |
| EP-2370407-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110237791-A1 | 2-PYRIDONE COMPOUNDS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-29 | — | — | US | disclosed |
| EP-2367797-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110230440-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | ADAMS JULIAN | 2011-09-22 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224262-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2073816-B1 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110206783-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2011-08-25 | — | — | US | disclosed |
| EP-2358371-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011076765-A1 | NOVEL ANTIVIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011073845-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947663-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-2308876-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | Novartis AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2011034828-A1 | SUBSTITUTED PARA-BIPHENYLOXYMETHYL DIHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
| US-20110034443-A1 | USES OF SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2011015641-A1 | NOVEL VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-02-10 | — | — | WO | disclosed |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2010-10-21 | — | — | US | disclosed |
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2234989-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| EP-2226317-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND, AND PROCESS FOR PRODUCTION THEREOF | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2215049-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| WO-2010080474-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010068242-A1 | PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-20100137249-A1 | COMPOSITIONS FOR REGULATING OR MODULATING QUORUM SENSING IN BACTERIA, METHODS OF USING THE COMPOUNDS, AND METHODS OF REGULATING OR MODULATING QUORUM SENSING IN BACTERIA | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137249-A1 | COMPOSITIONS FOR REGULATING OR MODULATING QUORUM SENSING IN BACTERIA, METHODS OF USING THE COMPOUNDS, AND METHODS OF REGULATING OR MODULATING QUORUM SENSING IN BACTERIA | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2010-06-03 | — | — | US | disclosed |
| WO-2010051188-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
| US-20100099134-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-04-22 | — | — | US | disclosed |
| WO-2010045420-A1 | METHODS FOR DETECTING SULFHYDRYL-CONTAINING COMPOUNDS IN A BIOLOGICAL TEST SAMPLE | THERAVANCE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| EP-2170350-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | Cara Therapeutics, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-2167091-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-20090318439-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| EP-2125826-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | Albany Molecular Research, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-1537104-B1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| EP-2100893-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | Novartis Ag (CH) | 2009-09-16 | — | — | EP | disclosed |
| US-20090221547-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2009-09-03 | — | — | US | disclosed |
| US-20090221547-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2009-09-03 | — | — | US | disclosed |
| US-20090221547-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2009-09-03 | — | — | US | disclosed |
| US-7579362-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2009-08-25 | — | — | US | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| WO-2009070583-A1 | PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2009058298-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK & CO., INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7517874-B2 | Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of pain | CARA THERAPEUTICS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1711183-A4 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2038264-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2009029317-A2 | COMPOSITIONS FOR REGULATING OR MODULATING QUORUM SENSING IN BACTERIA, METHODS OF USING THE COMPOUNDS, AND METHODS OF REGULATING OR MODULATING QUORUM SENSING IN BACTERIA | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090054446-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | NOVARTIS AG | 2009-02-26 | — | — | US | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318935-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155573-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157751-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157751-A2 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-7435455-B2 | Dihydrocoumarin derivative, liquid crystal composition containing the same, and liquid crystal display device | CHISSO CORPORATION (JP) | 2008-10-14 | — | — | US | disclosed |
| US-20080249127-A1 | Muscarinic Acetylcholine Receptor Antagonists | LAINE DRAMANE I | 2008-10-09 | — | — | US | disclosed |
| US-7425556-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| EP-1966158-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008086409-A1 | 5-FUROPYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| EP-1917240-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2008-05-07 | — | — | EP | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008000645-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2008000645-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| CN-1325493-C | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist | NOVARTIS AG (CH) | 2007-07-11 | — | — | CN | disclosed |
| WO-2007073283-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
| WO-2007024922-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024922-A1 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2007-03-01 | — | — | WO | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027150-A1 | 2-Amino-quinazolin-5-ones | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7141596-B2 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1711183-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2006-10-18 | — | — | EP | disclosed |
| US-20060167002-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | FEUERBACH DOMINIK | 2006-07-27 | — | — | US | disclosed |
| US-20060058326-A1 | Pyrimidines, methods for the production thereof, and use thereof | BASF AKTIENGESLLSCHAFT (DE) | 2006-03-16 | — | — | US | disclosed |
| US-20050272778-A1 | Inhibitors of proteins that bind phosphorylated molecules | INCYTE CORPORATION | 2005-12-08 | — | — | US | disclosed |
| EP-1592695-A1 | PYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-09 | — | — | EP | disclosed |
| CN-1678611-A | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist | NOVARTIS AG (CH) | 2005-10-05 | — | — | CN | disclosed |
| WO-2005067537-A2 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| EP-1537104-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005035551-A2 | INHIBITORS OF PROTEINS THAT BIND PHOSPHORYLATED MOLECULES | INCYTE CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2004069846-A1 | PYRIMIDINES, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004022556-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONIST | NOVARTIS AG (CH) | 2004-03-18 | — | — | WO | disclosed |
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2003101381-A2 | 1,2 DIAMIDO CYCLOALKYL SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| EP-1007512-B1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PROD INC (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6362195-B1 | INHIBITOR OF NITRIC OXIDE SYNTHASE; CENTRAL NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-03-26 | — | — | US | disclosed |
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | LOWE JOHN ADAMS (US) | 2002-02-21 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1007512-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | Pfizer Products Inc. (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999011620-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1999011620-A1 | BRANCHED ALKOXY-SUBSITUTED 2-AMINOPYRIDINES AS NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103459-A1 | SUBSTITUTED AZACYLES AS TRPM8 MODULATORS | TRPM8, TRPM7, TRPM5 | CA2 184/4885LPL 2835/4885LIPG 2646/4885 |
| US-20020022642-A1 | Branched alkoxy-subsituted 2-aminopyridines | NOS3, NOS2, PNMT | CA2 1708/4885LPL 2210/4885LIPG 1930/4885 |
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | CA2 1948/4885LPL 1201/4885LIPG 1011/4885 |
| US-20100256386-A1 | ARYL (1H-1,2,4-TRIAZOL-1-YL) COMPOUND AND PROCESS FOR PRODUCTION THEREOF | CYP1A1, CYP2S1, NAT1 | CA2 2112/4885LPL 3959/4885LIPG 4670/4885 |
| US-20120316161-A1 | NOVEL ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | CA2 4662/4885LPL 4274/4885LIPG 2297/4885 |
| US-20140128376-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | CA2 1868/4885LPL 4807/4885LIPG 4521/4885 |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, LCT, HAX1 | CA2 2300/4885LPL 541/4885LIPG 482/4885 |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | PDE12, PDE5A, PDE3A | CA2 2474/4885LPL 56/4885LIPG 163/4885 |
| US-20120214805-A1 | BRIDGED BICYCLIC PIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GPR180, GPR84 | CA2 2557/4885LPL 607/4885LIPG 407/4885 |
| US-20120058988-A1 | CARBAZOLE AND CARBOLINE KINASE INHIBITORS | JAK2, JAK1, JAK3 | CA2 1140/4885LPL 4723/4885LIPG 3730/4885 |
| US-20130096141-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR139 | CA2 3699/4885LPL 143/4885LIPG 103/4885 |
| US-20250304580-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | CA2 3043/4885LPL 2250/4885LIPG 1101/4885 |
| US-10570090-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | CYP19A1, ESR1, GPER1 | CA2 2985/4885LPL 2811/4885LIPG 2615/4885 |
| US-20110251176-A1 | PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE | PIM1, PIM2, PIM3 | CA2 1868/4885LPL 4807/4885LIPG 4521/4885 |
| US-20110224171-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | CA2 1331/4885LPL 180/4885LIPG 272/4885 |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | CA2 825/4885LPL 3680/4885LIPG 4232/4885 |
| US-20150183794-A1 | AZA-BICYLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CA2 2082/4885LPL 3159/4885LIPG 3588/4885 |
| US-20120129840-A1 | NOVEL VIRAL REPLICATION INHIBITORS | MAVS, EIF2AK2, SAMHD1 | CA2 4597/4885LPL 4441/4885LIPG 2518/4885 |
| US-10988467-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | CA2 3286/4885LPL 4306/4885LIPG 4548/4885 |
| US-20190071435-A1 | GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GLP1R, GCGR | CA2 2750/4885LPL 1105/4885LIPG 984/4885 |
| US-10344024-B2 | Compounds as ROR gamma modulators | RORB, RORA, RORC | CA2 3286/4885LPL 4306/4885LIPG 4548/4885 |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | MALT1, GUCY1A1, GUCY1B1 | CA2 924/4885LPL 3891/4885LIPG 3924/4885 |
| US-20170369487-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CA2 1017/4885LPL 4359/4885LIPG 4054/4885 |
| US-20150080340-A1 | BORONIC ACID CONJUGATES OF OLIGONUCLEOTIDE ANALOGUES | UPF1, RTCB, BCDIN3D | CA2 4008/4885LPL 4568/4885LIPG 4096/4885 |
| US-20170112814-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CA2 2008/4885LPL 3395/4885LIPG 3744/4885 |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | CA2 2008/4885LPL 3395/4885LIPG 3744/4885 |
| US-20230002390-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | CA2 3043/4885LPL 2250/4885LIPG 1101/4885 |
| US-20210177826-A1 | ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND | KDM1B, KDM1A, DOT1L | CA2 1905/4885LPL 3192/4885LIPG 3040/4885 |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | CA2 2722/4885LPL 1834/4885LIPG 966/4885 |
| US-10723742-B2 | Biphenyl compound or salt thereof | KDM1B, BMI1, HDAC1 | CA2 1411/4885LPL 1968/4885LIPG 1472/4885 |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | CA2 1948/4885LPL 1201/4885LIPG 1011/4885 |
| US-20250066401-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | CYBA, C1S, CYC1 | CA2 3325/4885LPL 3787/4885LIPG 4071/4885 |
| US-20250368605-A1 | Novel Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds, Processes for their Preparation and Therapeutic Uses Thereof | CYP19A1, ESR1, ESR2 | CA2 3145/4885LPL 3242/4885LIPG 2803/4885 |
| US-20120214789-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | CA2 1000/4885LPL 3978/4885LIPG 4735/4885 |
| US-20200277298-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | CA2 656/4885LPL 3306/4885LIPG 4323/4885 |
| US-20140206663-A1 | TRIAZINONE COMPOUNDS | THPO, IL5, CYP11B2 | CA2 3602/4885LPL 4786/4885LIPG 4850/4885 |
| US-20160355528-A1 | INHIBITORS OF HIV REPLICATION | RTF2, POLRMT, MAVS | CA2 4776/4885LPL 4739/4885LIPG 3346/4885 |
| US-12152042-B2 | Organometallic compound, organic light-emitting device including the same, and electronic apparatus including the organic light-emitting device | CYBA, C1S, CYC1 | CA2 3325/4885LPL 3787/4885LIPG 4071/4885 |
| US-20210300933-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | CA2 656/4885LPL 3306/4885LIPG 4323/4885 |
| US-20100266714-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | CA2 1691/4885LPL 3674/4885LIPG 4203/4885 |
| US-20190315687-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | CA2 3577/4885LPL 3963/4885LIPG 4316/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | CA2 3967/4885LPL 4578/4885LIPG 3784/4885 |
| US-20180078536-A1 | AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS | CHRNA7, CHRNA1, CHRNE | CA2 2008/4885LPL 3395/4885LIPG 3744/4885 |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CA2 1096/4885LPL 4665/4885LIPG 3969/4885 |
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | CA2 2291/4885LPL 2550/4885LIPG 4823/4885 |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | CA2 710/4885LPL 3940/4885LIPG 4190/4885 |
| US-20190040058-A1 | IMIDAZOPYRIDINES AND IMIDAZOPYRAZINES AS LSD1 INHIBITORS | KDM5A, KDM1A, KDM1B | CA2 1017/4885LPL 4359/4885LIPG 4054/4885 |
| US-20060167002-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | CA2 1968/4885LPL 3351/4885LIPG 3618/4885 |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | CA2 4643/4885LPL 2369/4885LIPG 2007/4885 |
| US-11479563-B2 | Biphenyl compound or salt thereof | BMI1, KDM1B, KDM1A | CA2 1568/4885LPL 2234/4885LIPG 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.